Free Trial
OTCMKTS:BIOQ

Bioqual 10/20/2023 Earnings Report

Bioqual logo
$43.19 0.00 (0.00%)
As of 07/14/2025

Bioqual EPS Results

Actual EPS
$1.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioqual Revenue Results

Actual Revenue
$15.58 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bioqual Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Bioqual Earnings Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
See More Bioqual Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioqual? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioqual and other key companies, straight to your email.

About Bioqual

Bioqual (OTCMKTS:BIOQ), Inc. is a preclinical contract research organization that specializes in in vivo and translational research services for the biotechnology and pharmaceutical industries. The company offers a range of disease‐relevant animal models, immunology assays and bioanalytical testing designed to support drug discovery, vaccine development and investigational new drug (IND) enabling studies. Bioqual’s service portfolio includes oncology, infectious disease, immunology and safety pharmacology models, allowing sponsors to accelerate lead optimization and candidate selection.

Founded in 2000 and headquartered in Rockville, Maryland, Bioqual operates state‐of‐the‐art research facilities that adhere to current Good Laboratory Practice (GLP) and Animal Welfare Act standards. The company’s team of scientific staff provides comprehensive study design, protocol development and regulatory support, helping clients navigate complex preclinical requirements. In addition to in vivo services, Bioqual offers specialized bioanalytical capabilities such as flow cytometry, immunogenicity testing and biomarker analysis.

Bioqual serves a global client base, including large pharmaceutical companies, emerging biotech firms and academic research institutions. Its facilities in the Washington, D.C., metropolitan area are complemented by flexible project management and quality assurance processes designed to meet both discovery‐stage research and IND regulatory milestones. The company’s foothold in a major life sciences hub enables seamless collaboration with contract development and manufacturing organizations, regulatory consultants and clinical research partners.

Bioqual’s leadership team comprises industry veterans with extensive backgrounds in translational science, immunology and preclinical development. Drawing on decades of collective experience, the management group focuses on expanding the company’s service offerings, enhancing model portfolios and implementing innovative technologies to support the evolving needs of clients across multiple therapeutic areas.

View Bioqual Profile

More Earnings Resources from MarketBeat